Global Expansion PackGene has established a tri-region operational network with offices in Boston, Houston and Zurich, plus a U.S. CDMO facility opened in December 2024. This indicates capacity for cross-border collaborations and expanded service delivery which sales can leverage to pitch multi-region gene therapy programs.

Awarded Leadership Frost & Sullivan recognized PackGene with global technology leadership awards in gene therapy CRDMO. This third-party validation can be used to build credibility with potential customers seeking proven partners for vector packaging, manufacturing and analytical services.

One‑Stop Solution The company offers an integrated package from plasmid and viral vector development through fill-finish and QC analytics. This positions PackGene as a convenient single vendor for end-to-end gene therapy programs, appealing to teams looking to simplify supply chains and accelerate timelines.

Thought Leadership Active participation in major conferences (ASGCT 2026) with multiple presentations on AAV vector development, scalable manufacturing and analytics demonstrates ongoing innovation and readiness to engage with potential clients, regulators and collaborators.

Mid‑Market Growth Reported revenue range of 10–25 million with financing of 14 million, and a workforce of 51–200, placing PackGene in a growth-ready segment attractive to mid-size biotech and early-stage gene therapy programs seeking scalable capacity without large enterprise overhead.